Search Results - "Jersemann, Katja"

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial by Beyer-Westendorf, Jan, Prof, Schellong, Sebastian M, Prof, Gerlach, Horst, MD, Rabe, Eberhard, Prof, Weitz, Jeffrey I, Prof, Jersemann, Katja, PhD, Sahin, Kurtulus, PhD, Bauersachs, Rupert, Prof

“…Summary Background Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism. Rivaroxaban, an oral factor Xa inhibitor, might…”
Get full text

Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial by Beyer-Westendorf, Jan, Schellong, Sebastian, Gerlach, Horst, Jersemann, Katja, Rabe, Eberhard, Sahin, Kurtulus, Bauersachs, Rupert

“…▪ Background The current standard of therapy in superficial vein thrombosis (SVT) comprises subcutaneous injections of the indirect…”
Get full text

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO by Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Diaz, Jose Miguel Torregrosa, De Renzis, Benoit, Götze, Katharina S., Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Borhane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Schipp, Dorothea, Metzeler, Klaus H., Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Platzbecker, Uwe, Adès, Lionel

“…The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with…”
Get full text

Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents by Kubasch, Anne Sophie, Peterlin, Pierre, Cluzeau, Thomas, Götze, Katharina S., Sockel, Katja, Teipel, Raphael, Jentzsch, Madlen, Kayser, Sabine, Attalah, Habiba, Chermat, Fatiha, Gloaguen, Silke, Jersemann, Katja, Schipp, Dorothea, Giagounidis, Aristoteles, McPherson, Stuart, Tirado-González, Irene, van de Loosdrecht, Arjan, Fenaux, Pierre, Platzbecker, Uwe, Medyouf, Hind, Ades, Lionel

“…*AK, PP shared first-, UP, HM, LA shared senior authors Introduction: Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk…”
Get full text

Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial by Kubasch, Anne Sophie, Schulze, Freya, Götze, Katharina S., Krönke, Jan, Sockel, Katja, Middeke, Jan Moritz, Chermat, Fatiha, Gloaguen, Silke, Puttrich, Martin, Weigt, Carmen, Jersemann, Katja, Fenaux, Pierre, Schlenk, Richard F., Giagounidis, Aristoteles, Ades, Lionel, Mies, Anna, Oelschlaegel, Uta, Platzbecker, Uwe

“…Introduction Recently, progress has been made in the treatment of patients with higher risk myelodysplastic syndromes (HR MDS) and acute myeloid leukemia…”
Get full text

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia by Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Torregrosa Diaz, Jose Miguel, De Renzis, Benoit, Götze, Katharina S., Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Bohrane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Schipp, Dorothea, Metzeler, Klaus H., Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Platzbecker, Uwe, Ades, Lionel

“…*UP, LA contributed equally Introduction A significant proportion of lower risk (LR)-MDS patients present with thrombocytopenia, being associated with…”
Get full text

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network by Platzbecker, Uwe, Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Torregrosa Diaz, Jose Miguel, De Renzis, Benoit, Götze, Katharina, Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Borhane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Ades, Lionel

“…Introduction: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and peripheral cytopenia. In about half of patients with…”
Get full text

Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply by Beyer-Westendorf, Jan, Schellong, Sebastian M, Gerlach, Horst, Rabe, Eberhard, Weitz, Jeffrey I, Jersemann, Katja, Sahin, Kurtulus, Bauersachs, Rupert

Get full text